12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Other News

Sygnis Pharma diagnostic news

Sygnis said it will reduce headcount by 10 (30%) to 23 and discontinue its KIBRA R&D project. The company said it was not possible to out-license the project within the available timeline and the project could not be...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >